Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. The company offers Optimer platform that enables the discovery and development of oligonucleotide binders; custom development services for oligonucleotide-based aptamer and Optimer binders; solutions to bioprocessing, diagnostic, and pharmaceutical scientists; and contract research services in the field of therapeutics. It serves pharma companies, diagnostic development companies, and research institutes. Aptamer Group plc was founded in 2008 and is headquartered in York, the United Kingdom.
Stock data | 2023 | Change |
---|---|---|
Price | $0.0031680240769829853 | N/A |
Market Cap | $218.77K | N/A |
Shares Outstanding | 69.06M | 6.99% |
Employees | 46.00 | N/A |
Shareholder Equity | 304.00K | -96.22% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.03 | N/A |
P/S Ratio | 0.09 | N/A |
P/B Ratio | 0.72 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -34.0250 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.31M | N/A |
Earnings | -$10.34M | N/A |
EPS | -0.1135 | N/A |
Earnings Yield | -35.83 | N/A |
Gross Margin | 0.2049 | N/A |
Operating Margin | -4.66 | N/A |
Net income margin | -4.47 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $3.63M | N/A |
Total Debt | $1.42M | N/A |
Cash on Hand | $308.88K | N/A |
Debt to Equity | $10.63 | 1769.65% |
Cash to Debt | 0.2171 | -95.76% |
Current Ratio | 0.9671 | -74.42% |